Bitcoin's appeal is driven more by concerns over inflation and debt than by the Federal Reserve's interest rate cuts. U.S. inflation remains above the Fed's 2% target, with the personal consumption expenditures (PCE) price index rising about 20.1% from August 2021 to August 2026, causing a 16.7% drop in purchasing power. Both headline and core inflation rates are above the Fed's goal, reflecting ongoing financial challenges including bond market losses and global debt issues. Bitcoin is being discussed alongside gold and the dollar as part of reserve asset considerations amid these economic conditions. Upcoming PCE data for September will be released on October 29, which could further influence market perspectives.
Bitcoin's case and inflation concerns provide context for cryptocurrency trends. For readers following crypto markets, here is Pluang's snapshot as of Oct 21, 2026 03:41 WIB: 45 of 50 major cryptocurrencies rose today. BAT gained 4.63% to Rp3.601 with 84% sell orders, GRT rose 4.43% to Rp446 with 94% sell orders, and ALGO increased 3.71% to Rp2.040 with 62% sell orders.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
